卵巢良恶性肿瘤组织中突变型p53、hMLH1、hMSH2的表达及临床意义  

Expressions and clinical significance of mutant p53 gene,DNA mismatch repair gene 1 and mismatch repair gene 2 in be-nign or malignant ovarian tumors tissues

作　　者：罗寿召 何英 LUO Shouzhao;HE Ying(Neijiang Hospital of Traditional Chinese Medicine,Neijiang,Sichuan Province,641000)

机构地区：[1]四川省内江市中医医院,641000

出　　处：《中国计划生育学杂志》2024年第9期2146-2151,共6页Chinese Journal of Family Planning

摘　　要：目的:研究突变型p53基因(Mt-p53)和DNA错配修复基因1(hMLH1)、错配修复基因2(hMSH2)在卵巢良恶性肿瘤中的表达及临床意义。方法:回顾性分析2017年7月-2021年7月本院收治的95例卵巢肿瘤患者临床资料,按照病理结果分为卵巢良性肿瘤组32例、交界性肿瘤组21例、恶性肿瘤组42例。分析对比不同病理类型、病理特征及预后的卵巢肿瘤组织中Mt-p53、hMLH1、hMSH2表达情况;统计2年内恶性肿瘤患者的生存率,采用受试者工作特征(ROC)曲线分析hMLH1、hMSH2表缺失对恶性卵巢肿瘤患者预后的预测效能。结果:恶性肿瘤组织中的Mt-p53阳性率(88.1%)高于交界性肿瘤组织(23.8%)、良性肿瘤组织(9.4%),hMSH1(66.7%)、hMSH2(61.9%)阳性率均低于交界性肿瘤组织(90.5%、90.5%)及良性肿瘤组织(100.0%、100.0%);恶性生殖细胞肿瘤组织hMLH1及hMSH2阳性率均低于卵巢上皮性癌组织,中-高分化恶性卵巢肿瘤组织hMLH1及hMSH2阳性率高于低分化组织,Mt-p53阳性率低于低分化组织;随访2年恶性肿瘤患者总生存率为54.8%,生存组Mt-p53阳性率(78.3%)低于死亡组(100%),hMLH1(87.0%)及hMSH2阳性率(82.6%)均高于死亡组(42.1%、36.8%)(均P<0.05)。19例死亡患者均存在p53基因突变,且其中11例存在hMLH1基因缺失、12例存在hMSH2缺失;ROC曲线分析,hMLH1及hMSH2基因缺失均对恶性卵巢肿瘤的预后有预测效能,曲线下面积分别为0.724、0.729(P<0.05)。结论:Mt-p53高表达、hMLH1及hMSH2基因缺失与卵巢恶性肿瘤的发生发展密切相关,且hMLH1及hMSH2基因缺失还可作为临床恶性肿瘤预后的预测指标。Objective:To study the expressions and clinical significance of mutant p53 gene(Mt p53),DNA mismatch repair gene 1(hMLH1)and mismatch repair gene 2(hMSH2)in benign or malignant ovarian tumors.Methods:The clinical data of 95 patients with ovarian tumors from July 2017 to July 2021 were analyzed retrospectively.These pa-tients were divided into 32 cases with benign ovarian tumor in group A,21 cases with borderline tumor in group B and 42 cases with malignant tumor in group C according to their pathological results.The expressions of Mt p53,hMLH1 and hMSH2 in the specimens of ovarian tumor of the patients with different pathological types,pathological features or prognosis status were analyzed and compared.The survival rate of the patients with malignant tumors within 2 years was counted.Receiver operating characteristic(ROC)curve was used to analyze the predictive efficiency of the dele-tions of hMLH1 and hMSH2 of the patients with malignant ovarian tumors for their prognosis.Results:The positive rate of Mt-p53(88.1%)of the patients in group C was significantly higher than that(23.8%)of the patients in group B and that(9.4%)of the patients in group A.The positive rates of hMSH1(66.7%)and hMSH2(61.9%)of the pa-tients in group C were significantly lower than those(90.5%and 90.5%)of the patients in group B and those(100.0%and 100.0%)of the patients in group A.The positive rates of hMLH1 and hMSH2 in the malignant germ cell tumors of the patients were significantly lower than those in the epithelial ovarian cancer.The positive rates of hMLH1 and hMSH2 in the moderately to highly differentiated malignant ovarian tumors of the patients were significantly higher than those in the poorly differentiated tissues,and the positive rate of Mt p53 in the moderately to highly differentiated malignant ovarian tumors of the patients was significantly lower than that in poorly differentiated tissues.The overall survival rate of the patients with malignant tumor in 2 years was 54.8%,and the positive rate of Mt-p53(78.3%)in.the surviv

关 键 词：卵巢良恶性肿瘤 突变型P53基因 DNA错配修复基因 临床意义 生存预后 

分 类 号：R737.31[医药卫生—肿瘤]